Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed

NCT04132674 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Human Immunodeficiency Virus I Infection
Drug Use

Interventions

DRUG: Bictegravir/emtricitabine/tenofovir alafenamide

Sponsor

Vancouver Infectious Diseases Centre